BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $552 | -3.7% | 8,114 | +17.4% | 0.06% | -27.6% |
Q4 2022 | $573 | -99.9% | 6,912 | +125.8% | 0.08% | -5.0% |
Q3 2022 | $869,000 | +155.6% | 3,061 | +212.0% | 0.08% | +175.9% |
Q2 2022 | $340,000 | +16.0% | 981 | +45.1% | 0.03% | +31.8% |
Q1 2022 | $293,000 | -77.2% | 676 | -74.5% | 0.02% | -80.5% |
Q3 2021 | $1,284,000 | +428.4% | 2,649 | +169.8% | 0.11% | +169.0% |
Q3 2020 | $243,000 | -31.0% | 982 | -38.7% | 0.04% | +23.5% |
Q4 2019 | $352,000 | -46.7% | 1,603 | -52.5% | 0.03% | -33.3% |
Q3 2019 | $660,000 | -38.0% | 3,372 | -33.9% | 0.05% | -17.7% |
Q2 2019 | $1,064,000 | -0.5% | 5,103 | -2.6% | 0.06% | -4.6% |
Q3 2018 | $1,069,000 | +193.7% | 5,241 | +113.1% | 0.06% | +306.2% |
Q2 2018 | $364,000 | +20.5% | 2,459 | -19.9% | 0.02% | -40.7% |
Q2 2015 | $302,000 | – | 3,070 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
Westwind Capital | 27,931 | $7,932,000 | 2.78% |
MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |